Cited by 888Gut microbiota and healthGlycosylation and Glycoproteins ResearchOral microbiology and periodontitis research

Fap2 Mediates Fusobacterium nucleatum Colorectal Adenocarcinoma Enrichment by Binding to Tumor-Expressed Gal-GalNAc

Open access
Abed, Jawad, Emgård, Johanna E.M., Zamir, Gideon, Faroja, Mouhammad, Almogy, Gideon, Grenov, Amalie, Sol, Asaf, Naor, Ronit +10 more·2016·Cell Host & Microbe

Abstract

Fusobacterium nucleatum is associated with colorectal cancer and promotes colonic tumor formation in preclinical models. However, fusobacteria are core members of the human oral microbiome and less prevalent in the healthy gut, raising questions about how fusobacteria localize to CRC. We identify a host polysaccharide and fusobacterial lectin that explicates fusobacteria abundance in CRC. Gal-GalNAc, which is overexpressed in CRC, is recognized by fusobacterial Fap2, which functions as a Gal-GalNAc lectin. F. nucleatum binding to clinical adenocarcinomas correlates with Gal-GalNAc expression and is reduced upon O-glycanase treatment. Clinical fusobacteria strains naturally lacking Fap2 or inactivated Fap2 mutants show reduced binding to Gal-GalNAc-expressing CRC cells and established CRCs in mice. Additionally, intravenously injected F. nucleatum localizes to mouse tumor tissues in a Fap2-dependent manner, suggesting that fusobacteria use a hematogenous route to reach colon adenocarcinomas. Thus, targeting F. nucleatum Fap2 or host epithelial Gal-GalNAc may reduce fusobacteria potentiation of CRC.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.chom.2016.07.006

Cites

49 of 49 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Metagenome analysis revealed a significant difference between the gut microbial composition of cancer patients and healthy individuals.

    “Metagenome analysis revealed a significant difference between the gut microbial composition of cancer patients and healthy individuals.”

    From Gut microbiota-mediated immunomodulation in tumor (2021) · cites this paper as [7]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Abed, J., Emgård, J. E. M., Zamir, G., Faroja, M., Almogy, G., Grenov, A., Sol, A., Naor, R., Pikarsky, E., Atlan, K. A., Mellul, A., Chaushu, S., Manson, A. L., Earl, A. M., Ou, N., Brennan, C. A., Garrett, W. S., & Bachrach, G.
Affiliations
  • Hebrew University of Jerusalem (IL)
  • Hadassah Medical Center (IL)
  • Broad Institute (US)
  • Harvard University (US)
Corresponding author
  • Garrett, Wendy S.
  • Bachrach, Gilad
Venue
Cell Host & Microbe
Publisher
Elsevier BV
Published
2016-08
Volume
20
Issue
2
Pages
215-225
ISSN
1931-3128 (ISSN-L)
OpenAlex
W2508695471
Cited by
888
References
49
Citations by year
2026: 112 · 2025: 155 · 2024: 109 · 2023: 117 · 2022: 112 · 2021: 81 · 2020: 69 · 2019: 48 · 2018: 45 · 2017: 33 · 2016: 5
FWCI
22.56
Type
journal article
Language
en
Open access
Locations
  • Cell Host & Microbe (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • Israel Cancer Research Fund
  • Israel Science Foundation
  • National Cancer Institute (R01CA154426)
  • National Institute of Allergy and Infectious Diseases (U19AI110818, K08AI078942)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Glycosylation and Glycoproteins Research
  • Health Sciences › Dentistry › Periodontics › Oral microbiology and periodontitis research
Keywords
Fusobacterium nucleatum, colorectal adenocarcinoma, bacterial lectins, O-glycosylation, tumor microenvironment, hematogenous spread, oral microbiota, therapeutic targeting
MeSH terms
Adenocarcinoma, Animals, Bacterial Adhesion, Colonic Neoplasms, Disease Models, Animal, Epithelial Cells, Humans, Mice, Inbred BALB C, Models, Biological, Protein Binding, Antigens, Tumor-Associated, Carbohydrate, Fusobacterium nucleatum, Adhesins, Bacterial, Lectins, Cell Line, Tumor, Host-Pathogen Interactions

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review